ReviewMolecular neurobiology2004
Humanin: after the discovery.
Review in Molecular neurobiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Preserving brain health in aging: structural and biochemical benefits of water based resistance training, a randomized controlled trial.BMC geriatrics · 2026Trial
- Inter- and intracellular mitochondrial communication: signaling hubs in aging and age-related diseases.Cellular & molecular biology letters · 2024Review
- Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities.Journal of advanced research · 2024Review
- Humanin activates integrin αV-TGFβ axis and leads to glioblastoma progression.Cell death & disease · 2024Article
- Stability Determination of Intact Humanin-G with Characterizations of Oxidation and Dimerization Patterns.Biomolecules · 2023Article
- Transcriptome analyses of the cortex and white matter of focal cortical dysplasia type II: Insights into pathophysiology and tissue characterization.Frontiers in neurology · 2023Article
- Pharmacologic enrichment of exosome yields and mitochondrial cargo.Mitochondrion · 2022Article
- S14G-humanin (HNG) protects retinal endothelial cells from UV-B-induced NLRP3 inflammation activation through inhibiting Egr-1.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Article
- MicroRNA Cues from Nature: A Roadmap to Decipher and Combat Challenges in Human Health and Disease?Cells · 2021Review
- Detection of mitochondria-pertinent components in exosomes.Mitochondrion · 2020Article
- Review
- Humanin, a Mitochondrial-Derived Peptide Released by Astrocytes, Prevents Synapse Loss in Hippocampal Neurons.Frontiers in aging neuroscience · 2019Article
- The Mitochondrial-Derived Peptides, HumaninS14G and Small Humanin-like Peptide 2, Exhibit Chaperone-like Activity.Scientific reports · 2017Article
- [Gly14]-Humanin Protects Against Amyloid β Peptide-Induced Impairment of Spatial Learning and Memory in Rats.Neuroscience bulletin · 2016Article
- Humanin Derivatives Inhibit Necrotic Cell Death in Neurons.Molecular medicine (Cambridge, Mass.) · 2015Article
- Mitochondrial Retrograde Signaling: Triggers, Pathways, and Outcomes.Oxidative medicine and cellular longevity · 2015Review
- Protective effects of Humanin and calmodulin-like skin protein in Alzheimer's disease and broad range of abnormalities.Molecular neurobiology · 2015Review
- Antiapoptotic factor humanin is expressed in normal and tumoral pituitary cells and protects them from TNF-α-induced apoptosis.PloS one · 2014Article
- Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents.Endocrinology · 2013Article
- Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Humanin (HN) is a novel neuroprotective factor that consists of 24 amino acid residues. HN suppresses neuronal cell death caused by Alzheimer's disease (AD)-specific insults, including both amyloid-beta (betaAbeta) peptides and familial AD-causative genes. Cerebrovascular smooth muscle cells are also protected from Abeta toxicity by HN, suggesting that HN affects both neuronal and non-neuronal cells when they are exposed to AD-related cytotoxicity. HN peptide exerts a neuroprotective effect through the cell surface via putative receptor(s). HN activates a cellular signaling cascade that intervenes (at least) in activation of c-Jun N-terminal kinase. The highly selective effect of HN on AD-relevant cell death indicates that HN is promising for AD therapy. Additionally, a recent study showed that intracellularly overexpressed HN suppressed mitochondria-mediated apoptosis by inhibiting Bax activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.